Dianthus Therapeutics, Inc. (NasdaqCM: DNTH)
Health Care · Biotechnology · US
$84.88
-0.61% today · +144.6% 1Y
Dianthus Therapeutics, Inc. (NasdaqCM: DNTH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.75B and employs 92 people.
Over the last twelve months the share price has gained 144.6%, trading between 32.22 and 117.88.
Tweenvest scores Dianthus Therapeutics, Inc. across four factors: quality 51/100, value 77/100. Its strongest factor is value.
DNTH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.75B
- Revenue (TTM)
- $1.90M
- P/E
- —
- EPS
- -4.11
- Dividend yield
- —
- Beta (5Y)
- 0.18
- 52-week high
- $117.88
- 52-week low
- $32.22
- Avg volume (3M)
- —
- Shares outstanding
- 55.93M
- Employees
- 92
- Next earnings
- —
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- ISIN
- US2528281080
- Founded
- 2019
- Listed since
- Jun 21, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CRISPR Therapeutics AGNasdaqGM: CRSP | $5.06B | $52.10 | -0.48% |
| Chongqing Zhifei Biological Products Co., Ltd.SZSE: 300122 | $4.99B | CN¥13.98 | +7.46% |
| 3SBio Inc.SEHK: 1530 | $4.99B | HK$15.70 | -1.94% |
| Erasca, Inc.NasdaqGS: ERAS | $4.94B | $14.12 | -1.26% |
| Lin BioScience, Inc.TPEX: 6696 | $4.72B | NT$181.50 | -8.33% |
| Shanghai Junshi Biosciences Co., Ltd.SEHK: 1877 | $4.67B | HK$18.07 | -1.31% |
| Suzhou Zelgen Biopharmaceuticals Co., Ltd.SHSE: 688266 | $4.34B | CN¥110.00 | +0.96% |
| Imeik Technology Development Co.,Ltd.SZSE: 300896 | $4.27B | CN¥95.00 | +3.34% |
Figures last refreshed Oct 4, 2026.